Experimental and clincal study on Zengshengping’s preventive effect on oral cancer

Wednesday, 10/08/2011  |   Herb or Compound  |  no comments

Experimental and clincal study on Zengshengping’s preventive effect on oral cancer
Objective To study and observe the preventive effect of Zengshengping on DMBA-induced hamster oral carcinogenesis and the clinical effect of Zengshengping on human oral leukoplakia, the precancerous lesion of oral cancer. Methods In experimental study, 50 male hamsters were randomly divided into 3 groups, the negative control group (10 hamsters), the Zengshengping treated group (20 hamsters) and the DMBA group (20 hamsters). The negative control group was only treated with acetone, the DMBA group treated with 0.5% DMBA three times per week for 6 weeks, the Zengshengping treated group treated with Zengshengping 6.0g/kg per day for 10 weeks after being treated the same as the DMBA group, and then observed visually and pathologically. At the same time, micronucleus, argentum nucleolar organizer regions(AgNOR) , proliferation cell nuclear antigen(PCNA )were examined. In clinical study, 112 patients with oral leukoplakia were randomly divided into two groups? treated group and 59 for the control group 53. The treated group was administered with Zengshengping 4 tablets each time and 3 times per day for 8 to 12 months; The control group was observed without treatment. Results The average tumor number and tumor burden of the treated group was remarkably lower than that of the DMBA group with the inhibition rate of 44.6% and 69.6% respectively. The canceration rate was 55.0%, much lower than 95.0% for the positive control group. Incidence of micronucleated cell, AgNOR number and PCNA labeling index of the treated group was evidently lower than that of the positive control group. The size of oral lesion decreased in 67. 8% of the patients in the treated group while only 16.9% in the placebo treatment group. Conclusion Zengshengping may revert and cure the precancerous lesion and lower the incidence rate of oral cancer. Zengshengping has certain therapeutic effects on the oral leukoplakia.
–Sun Zheng;Li Ning;Liu XiaoYong;Wang RongSun Zheng;Li Ning;Liu XiaoYong;Wang Rong. Bei Jing Kou Qiang Yi Xue. 2005; 13(3): 168-171.

Experimental study on the pharmacologic effects of Zeng Sheng Ping Pian.
Zeng Sheng Pin Pian (ZSPP)is a mixture of medicinal herbs which has been shown to be effective in the secondary prevention of esophageal cancer in a high -risk area among a population with severe esophageal dysplasia. This study in mice aimed at elucidating the possible mechanism ofthe cancer-preventing activity of ZSPP. The results indicate that ZSPP is a good biologic responsemodifier (BRM) as shown by its enhancing effects on lymphocyte blastogenesis, IL-2 secretion, NK cell activity, delayed-type hypersensitivity reation to DNCB, hemolysin response to SRBC and the phagocytic function of the reticulo-endothelial system. While ZSPP did not inhibit the growth of S-180 in mice, it exhibited significant inhibitory effect on ornighine decarboxylast (ODC) activity induced by the application of croton oil to the skin. Taken together, the immune enhancing activity and the anti-tumor promoting activity of ZSPP could explain, at least in part, its efficacy in the prevention of esophageal cancer among high-risk people iwth precursor dysplastic lesions.
–Wang Dechang; Wang Debin; Zhang Jingshen. Zhang Jin, Wang Yongquan, Zhang Lisheng, Xu Guozeng, Cao Minghua, Gao Feng, Guo Changyue, Fu Zhaodi, Han Rui. Zhong Hua Zhong Liu Za Zhi. 1994; (6): 419-424.

Observing the clinical therapeutic effect of zengshengping in intestinal metaplasia
Objective: To observe the clinical therapeutic effect of zengshengping in intestinal metaplasia(IM). Methods: The reversion of intestinal metaplasia in 99patients with IMwho has taken zengshengping for12months were observed. Results: The effective rate of zengshengping in the treatment of IMwas59.6%, the adverse reaction was 1.98%. Conclusion: Zengshengping has a certain therapeutic effect in IM,with very fewadverse reaction and good compliance.
–Zhu Xuqing, Xu Sanrong, Wang Guoxiang. Xian Dai Yi Yao Wei Sheng. 2005; 21(1): 10-10.

Treatment of 108 Cases with Epithelial Cell Hyperplasia of Esophagus by Zengshengping Tablet.
Epithelial hyperplasia of esophagus as a precaneerous lesion was clinically treated by Zengshengping tablets. Both improvement of clinical symptoms and examination by fiberoptic esophagoscopy or pathological biopsy appeared to favour more the tablet therapy than the control one. The tablet was found to be more potent against the epithelial hyperplasia with a syndrome of heat stagnation in the interior than the one with a syndrome of stagnation of Liver-qi.
–Wang Junxian, Zhou Erfu, Ding Zhenwei , Wang Jixin, Guo Liping. Zhong Guo Shi Yan Fang Ji Xue Za Zhi. 1997; 3(1): 28-30.

Results of phase III clinical trial of Zeng Sheng ping in the treatment of patients with esophageal epithelial hyperplasia
Objective Through a multi center randomized, single blinded and placebo controlled trial to evaluate the therapentic effect of Zeng Sheng ping (ZSP) on esophageal epithelial hyperplasia in a population with high risk of esophageal cancer. Methods The residents between 40 and 65 years of age in Ci County of Hebei Province were screened by balloon cytological examinations of the esophagus. Patients with esophageal epithelial hyperplasia were further confirmed by biopsy with esophagoscopy. They were randomly stratified into different arms according to sex, age and the grade of hyperplastic lesions. A total of 449 with esophageal epithelial hyperplasia were eligible and randomized into ZSP group and placebo group. In ZSP group, 300 patients received oral ZSP 8 tablets, twice a day for 6 months. There were 149 patients in the placebo group. To ensure the accuracy of the trial riboflavin was added into ZSP and placebo group as an indicator of compliance and urine samples were periodically examined. Results: after 6 months of treatment, the response rate was 64.4% (193/300) in ZSP group and 22.8% (34/149) in the placebo group. There was a statistically significant difference between the two groups (P

Leave a Reply

You must be logged in to post a comment.